Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kivu Bioscience has completed a $92m Series A funding round, spearheaded by Novo Holdings to propel the development of next-generation antibody-drug conjugates (ADCs).
The funds will be channelled towards advancing Kivu’s multiple oncology programmes into clinical trials. Credit: JOSHUA COLEMAN on Unsplash.
Subscribe to our email newsletter
The investment round saw contributions from Gimv, HealthCap, Red Tree Venture Capital, and existing backers BioGeneration Ventures, M Ventures, and Brabantse Ontwikkelings Maatschappij (BOM).
The funds will be channelled towards advancing multiple oncology programmes into clinical trials.
Through this funding, Kivu also aims to advance its Topo1i-based ADC pipeline to clinics.
Kivu Bioscience president and chief operating officer Mohit Trikha said: “We’re excited to have the backing of this top-tier syndicate, who share our vision for developing kinder, gentler ADC therapies that are more effective and safer for cancer patients.
“Our next-generation ADCs address key limitations of current treatments, particularly by engineering stable ADCs we have the potential to reduce off-target side effects which in turn widens the therapeutic window. We are inspired by patients and driven by data to accelerate transformative medicines.”
The company leverages its Synaffix site-specific linker-payload technology, GlycoConnect, to develop ADC therapeutics.
The GlycoConnect technology attaches the linker to asparagine-297 to offer a “highly” homogenous product.
This technology is claimed to simplify manufacturing and enhance the ADC’s stability, to significantly reduce the risk of off-target side effects.
By improving the therapeutic gap, Kivu aims to improve the patient safety profile and address the high discontinuation and dose-reduction rates associated with current ADC treatments. This advancement could be crucial for the treatment of solid tumours.
Kivu is currently preparing to initiate Phase I trials for its lead candidate in 2025.
